<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688294</url>
  </required_header>
  <id_info>
    <org_study_id>3/2019</org_study_id>
    <nct_id>NCT04688294</nct_id>
  </id_info>
  <brief_title>The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure</brief_title>
  <official_title>The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amir Safwat</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suez Canal University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the bio-clinical effects of sacubitril/valsartan&#xD;
      combination in treatment of patients with Congestive heart failure. Moreover, the&#xD;
      investigators aim to evaluate side effects of this combination.&#xD;
&#xD;
      - The following parameters were determined at baseline and at end of the study at 6 months of&#xD;
      the beginning.&#xD;
&#xD;
        1. New York Heart Association (NYHA) Class.&#xD;
&#xD;
        2. Frequency of hospitalization by acute exacerbation of CHF&#xD;
&#xD;
        3. NT-ProBNP&#xD;
&#xD;
        4. Left ventricular systolic function by Echocardiography&#xD;
&#xD;
      Moreover, the side effects of the drugs used during study was assessed by&#xD;
&#xD;
        1. Renal function (Serum creatinine) was performed every month till the end of the study.&#xD;
&#xD;
        2. Serum electrolytes (Potassium and Sodium) was performed every month till the end of the&#xD;
           study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in NTproBNP plasma concentration</measure>
    <time_frame>at baseline</time_frame>
    <description>NTproBNP is a Biomarker used to assess severity of congestive heart failure)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in NTproBNP plasma concentration</measure>
    <time_frame>at 6 months</time_frame>
    <description>NTproBNP is a Biomarker used to assess severity of congestive heart failure)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>severity of congestive heart failure.</measure>
    <time_frame>at baseline</time_frame>
    <description>Ejection fraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>severity of congestive heart failure.</measure>
    <time_frame>at 6 months</time_frame>
    <description>Ejection fraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in plasma potassium concentration</measure>
    <time_frame>every month, up to 6 months</time_frame>
    <description>plasma potassium (intracellular cation) concentration used to evaluate Sacubitril-Valsartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum sodium concentration</measure>
    <time_frame>every month, up to 6 months</time_frame>
    <description>serum sodium (extracellular cation) concentration used to evaluate Sacubitril-Valsartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum creatinine</measure>
    <time_frame>every month, up to 6 months</time_frame>
    <description>serum creatinine which is a byproduct of muscle protein metabolism is used to evaluate Sacubitril-Valsartan</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Sacubitril/valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 30 patients will undergo treatment with sacubitril/valsartan combination according to guideline-directed medical therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 30 patients will undergo treatment with valsartan according to guideline-directed medical therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril-Valsartan</intervention_name>
    <description>Study participants initially received Sacubitril/Valsartan at 49 mg/51 mg twice daily orally then dose was doubled as tolerated every 2-4 weeks to reach the target maintenance dose 97 mg/103 mg twice daily</description>
    <arm_group_label>Sacubitril/valsartan</arm_group_label>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 40 - 60 years&#xD;
&#xD;
          2. Patients with chronic congestive heart failure class ( II-IV) symptoms according to&#xD;
             New York Heart Association (NYHA) classification&#xD;
&#xD;
          3. Left Ventricular Ejection Fraction of 40% or less.&#xD;
&#xD;
          4. NT-proBNP level of at least ≥400 pg per milliliter&#xD;
&#xD;
          5. ACE-inhibitor or ARB therapy with stable dose for prior 4 weeks, equivalent to&#xD;
             enalapril ≥ 10 mg/day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with symptomatic hypotension.&#xD;
&#xD;
          2. Pregnant and nursing women&#xD;
&#xD;
          3. Patients with implanted cardiac devices (e.g. Pacemakers)&#xD;
&#xD;
          4. Systolic blood pressure &lt; 100 mmHg at screening or &lt; 95 mmHg at randomization&#xD;
&#xD;
          5. Patients with glomerular filtration rate &lt;30 mL/min/1.73 m2&#xD;
&#xD;
          6. Patients with history of angioedema&#xD;
&#xD;
          7. Patients with unacceptable side effects with ACE-inhibitors or ARBs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amir Safwat</last_name>
    <phone>01111630833</phone>
    <email>amir_safwat@pharm.suez.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hoda Salem</last_name>
    <phone>01000007613</phone>
    <email>hodasalem2000@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wadi El-Neel Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11865</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hazem Khamis</last_name>
      <phone>01001625073</phone>
      <email>Hazemkhamis62@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Suez Canal University</investigator_affiliation>
    <investigator_full_name>Amir Safwat</investigator_full_name>
    <investigator_title>Teaching assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

